Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) major shareholder Vii Lp Canaan sold 20,589 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $1.81, for a total transaction of $37,266.09. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Vii Lp Canaan also recently made the following trade(s):
- On Tuesday, July 26th, Vii Lp Canaan sold 20,380 shares of Marinus Pharmaceuticals stock. The shares were sold at an average price of $1.81, for a total transaction of $36,887.80.
- On Monday, July 25th, Vii Lp Canaan sold 270,750 shares of Marinus Pharmaceuticals stock. The shares were sold at an average price of $1.90, for a total transaction of $514,425.00.
MRNS has been the subject of a number of analyst reports. Jefferies Group restated a “buy” rating and set a $2.50 price objective (down from $13.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 14th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, May 3rd. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Tuesday, July 5th. Stifel Nicolaus restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 28th. Finally, Goldman Sachs Group Inc. lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 14th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $7.80.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.04. On average, equities research analysts expect that Marinus Pharmaceuticals Inc. will post ($1.47) earnings per share for the current year.
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
